Nkarta Inc
NKTX1.970USD
+0.020+1.03%
收盤 11/06, 16:00（美東）報價延遲15分鐘
139.92M總市值
虧損本益比TTM
關於 Nkarta Inc 公司
Nkarta, Inc. 是一家臨牀階段的生物製藥公司，致力於開發同種異體、現成的工程化自然殺傷 (NK) 細胞療法，用於治療患有自身免疫性疾病或血液系統惡性腫瘤的患者。該公司正在開發 NKX019，一種針對 CD19 抗原的嵌合抗原受體-自然殺傷 (CAR NK) 候選產品和 NKX101，一種針對展示 NKG2D 配體的細胞的 CAR NK 候選產品。這兩種候選產品均支持按需、現成的方法，包括規模化生產以擴大患者的使用範圍。其 NKX019 自身免疫計劃基於消除產生自身抗體的病理性 B 細胞的潛力。其 NKX019 腫瘤學計劃基於通過靶向可靠表達在這些類型的癌細胞上的 CD19 抗原來治療多種 B 細胞惡性腫瘤的潛力。其 NKX101 項目旨在增強先天 NK 細胞生物學檢測和殺死癌細胞的能力。
Nkarta Inc簡介
公司代碼NKTX
公司名稱Nkarta Inc
上市日期Jul 10, 2020
CEOMr. Paul J. Hastings
員工數量157
證券類型Ordinary Share
年結日Jul 10
公司地址1150 Veterans Boulevard
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話19254071049
網址https://www.nkartatx.com/
公司代碼NKTX
上市日期Jul 10, 2020
CEOMr. Paul J. Hastings
Nkarta Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
107.34K
-1.64%
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
--
--
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Ms. Angela Thedinga
Ms. Angela Thedinga
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
107.34K
-1.64%
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
--
--
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
收入明細
FY2020
FY2019
FY2018
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
15.21%
Tang Capital Management, LLC
9.93%
Samsara BioCapital, LLC
5.31%
BlackRock Institutional Trust Company, N.A.
5.15%
New Enterprise Associates (NEA)
5.02%
其他
59.38%
持股股東
持股股東
佔比
RA Capital Management, LP
15.21%
Tang Capital Management, LLC
9.93%
Samsara BioCapital, LLC
5.31%
BlackRock Institutional Trust Company, N.A.
5.15%
New Enterprise Associates (NEA)
5.02%
其他
59.38%
股東類型
持股股東
佔比
Venture Capital
34.23%
Hedge Fund
20.86%
Investment Advisor
15.62%
Investment Advisor/Hedge Fund
13.05%
Corporation
4.45%
Research Firm
2.49%
Individual Investor
0.82%
Family Office
0.12%
Bank and Trust
0.09%
其他
8.26%
機構持股
更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
267
61.29M
86.29%
-28.01M
2025Q2
285
69.55M
98.01%
-21.71M
2025Q1
300
69.02M
97.27%
-22.80M
2024Q4
316
69.51M
100.26%
-10.53M
2024Q3
335
73.98M
106.61%
-9.96M
2024Q2
333
73.31M
105.81%
-2.74M
2024Q1
329
70.79M
102.89%
+13.14M
2023Q4
312
47.25M
96.07%
-11.76M
2023Q3
310
42.86M
87.43%
-15.68M
2023Q2
313
46.09M
94.31%
-14.43M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
10.81M
15.21%
--
--
Jun 30, 2025
Tang Capital Management, LLC
7.06M
9.93%
--
--
Jun 30, 2025
Samsara BioCapital, LLC
3.77M
5.31%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.66M
5.15%
-352.29K
-8.79%
Jun 30, 2025
New Enterprise Associates (NEA)
3.57M
5.02%
--
--
Jun 30, 2025
SR One Capital Management, LP
3.33M
4.69%
--
--
Jun 30, 2025
Citadel Advisors LLC
3.30M
4.64%
-210.67K
-6.00%
Jun 30, 2025
GSK plc
3.16M
4.45%
+3.16M
--
Mar 27, 2024
EQT Life Sciences
2.84M
3.99%
--
--
Feb 12, 2025
The Vanguard Group, Inc.
2.55M
3.6%
+29.18K
+1.16%
Jun 30, 2025
查看更多
持股ETF
更新時間: 18 小時前
更新時間: 18 小時前
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0%
ProShares Hedge Replication ETF
佔比0%
Invesco Raymond James SB-1 Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
